Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company's senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis' guidance reflects continued growth for CABO, driven by the company's existing business and the launch in neuroendocrine tumors, or NETs. He said the company is focused on gaining market share in renal cell carcinoma, or RCC ...